Breast cancer and prostate cancer assessment

• US 20070148712A1
• Filed: 06/08/2006
• Published: 06/28/2007
• Est. Priority Date: 06/08/2005
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Nebraska
• Original Assignee: Board of Regents of the University of Nebraska, Iowa State University Research Foundation Incorporated (Iowa State University)
• Inventors: Cavalieri, Ercole, Rogan, Eleanor, Saeed, Muhammad, Jankowiak, Ryszard, Markouchine, Iouri
• Application Number:
  US11/450,808
• Publication Number:
  US 20070148712A1
• Time in Patent Office: Days
• US Class Current: 435/7.230
• CPC Class Codes: G01N 2333/723 Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57434 of prostate
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids
• CPC Class Codes: G01N 33/743 Steroid hormones

Abstract

A method for detecting a biological marker in a sample, which comprises a complex mixture of molecules, from a patient comprising exposing a detection site having bound monoclonal antibodies specific for the biological marker to the sample, exposing the detection site to a detectably labeled reporter molecule, which is substantially identical to the biological marker, and assessing the degree of binding at the detection site by the reporter molecule; reporter molecules; haptens; and monoclonal antibodies.

Claims

1. A method for detecting a biological marker in a sample, which comprises a complex mixture of molecules, from a patient, which method comprises:

exposing a detection site having bound monoclonal antibodies specific for the biological marker to the sample;

washing the detection site with a solution that removes substantially unbound molecules from the detection site;

exposing the detection site to a reporter molecule, which is substantially identical to the biological marker, wherein the reporter molecule is detectably-labeled;

washing the detection site with a solution that removes substantially unbound reporter molecules from the detection site; and

assessing the degree of binding at the detection site by the reporter molecule, wherein a high degree of binding by the reporter molecule is indicative of an absence or a low concentration of the biological marker in the sample, and wherein an absence or a low degree of binding by the reporter molecule is indicative of a high concentration or moderate concentration of the biological marker in the sample.

2. The method of claim 1, wherein the biological marker is a conjugate (and/or DNA adduct) derived from catechol estrogen quinone.

3. A reporter molecule selected from the group consisting of a 4-OHE₁-2-N-AcCys conjugate, a 4-OHE₂-2-N-AcCys conjugate, a 4-OHE₁-1-N3 Ade adduct, and a 4-OHE₂-1-N3 Ade adduct, and wherein the reporter molecule is detectably-labeled.

4. A monoclonal antibody having specificity for 4-OHE₁-2-N-AcCys and 4-OHE₂-2-N-AcCys conjugates.

5. A monoclonal antibody having specificity for 4-OHE₁-1-N3 Ade and 4-OHE₂-1-N3 Ade and/or 4-OHE₁-1-N7 Gua and 4-OHE₂-1-N7 Gua adducts.

6. A hapten selected from the group consisting of 4-OHE₁/E₂-2-NAcCys-16-MCC, 4-OH-17AM-E₂-2-NAcCys-MCC, and 4-OH-17-AM-E₂-1-N3Ade-MCC, any one of which is optionally labeled with a detectable label.

7. A biochip comprising a monoclonal antibody having specificity for a conjugate and/or a DNA adduct derived from CEQ.

8. A kit comprising the biochip of claim 7, a hapten, and a reporter molecule.